A Phase IIa, Double-Blind, Mechanistic Study of GSK3196165 in Combination With Methotrexate Therapy in Subjects With Active Rheumatoid Arthritis Despite Treatment With DMARDs
Latest Information Update: 31 Aug 2023
At a glance
- Drugs Otilimab (Primary) ; Folic acid; Methotrexate; Methotrexate
- Indications Rheumatoid arthritis
- Focus Biomarker; Pharmacodynamics
- Sponsors GlaxoSmithKline; GSK
- 24 Oct 2018 Results presented at the 82nd American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting
- 22 Nov 2017 Status changed from active, no longer recruiting to completed.
- 12 Jul 2017 Planned End Date changed from 6 Oct 2017 to 19 Oct 2017.